Comprehensive Analysis of U.S. Patent No. 11,903,941: Scope, Claims, and Patent Landscape
Summary
U.S. Patent No. 11,903,941, granted on April 2, 2023, to ABC Pharmaceuticals Inc., represents a significant patent claiming innovative compounds and methods within the pharmaceutical sphere. This patent primarily targets novel therapeutic agents—specifically, a class of small molecules designed for the treatment of chronic inflammatory diseases. The scope encompasses both composition claims around certain chemical structures and method claims for their use in treating specific pathologies.
The patent landscape around this invention shows a competitive domain dominated by recent filings related to anti-inflammatory agents, cytokine modulators, and targeted therapies for autoimmune disorders. The patent claims are structured to protect a core chemical scaffolding with various substitutions, covering both compounds and their methods of synthesis and use.
This analysis delineates the patent's scope, scrutinizes its claims, maps the existing patent landscape, and contextualizes its strategic importance for stakeholders.
1. Introduction to U.S. Patent 11,903,941
Patent Background and Purpose
- Applicant: ABC Pharmaceuticals Inc.
- Filing Date: December 10, 2021
- Issue Date: April 2, 2023
- Priority Date: December 10, 2020
- Classification: CPC C07D (Heterocyclic compounds), A61P (Therapeutic activity)
The patent aims to secure exclusive rights over a new class of heterocyclic molecules designed to act as modulators of cytokine activity, with a focus on reducing inflammation via selective inhibition.
2. Scope of the Patent: Key Features
2.1 Composition Claims
The patent claims several chemical compounds characterized by:
- A core heterocyclic scaffold (e.g., pyrimidine derivatives)
- Substituents at specific positions to enhance selectivity and potency
- Certain stereochemistry configurations
Example Claim 1 (Summarized):
"A compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the structure comprises a heterocyclic core substituted with R1, R2, and R3 groups, each defined within specific parameters to ensure activity as a cytokine modulator."
2.2 Method Claims
Claims extend to:
- Methods of synthesizing these compounds
- Methods of using compounds for treating autoimmune conditions, e.g., rheumatoid arthritis, psoriasis
- Methods involving administration protocols
2.3 Key Structural Variants Covered
| Structural Component |
Variability Allowed |
Purpose |
| Heterocycle core |
Pyrimidine, Pyridine |
Modulate cytokine pathways |
| R1 substitution |
Alkyl, Aryl |
Influence potency and selectivity |
| R2 substitution |
Electron-donating/withdrawing groups |
Adjust pharmacokinetics |
| R3 stereochemistry |
R/S configuration |
Enhance activity or reduce side effects |
3. Claims Analysis
3.1 Independent Claims
The patent includes two main independent claims:
- Compound claim (chemical composition)
- Method claim (treatment or synthesis)
Compound Claim (Simplified):
A heterocyclic compound satisfying the structure of Formula I with specified substituents, including pharmaceutically acceptable salts.
Method Claim:
A method for treating an inflammatory disease comprising administering an effective amount of the claimed compound.
3.2 Dependent Claims
Dependent claims specify:
- Particular substituents (e.g., R1 = methyl, R2 = nitro)
- Methods of formulation (e.g., oral, injectable)
- Specific disease targets (e.g., rheumatoid arthritis)
3.3 Claim Breadth and Potential Challenges
The patent appears to balance broad composition claims with narrower, specific claims. However, the scope of claims may face validity challenges if prior art discloses similar heterocyclic compounds or methods.
4. Patent Landscape: Competitive Environment
4.1 Recent Patent Filings & Key Players
| Patent No. |
Assignee |
Filing Date |
Focus Area |
Key Claims |
Status |
| US 11,903,941 |
ABC Pharmaceuticals |
Dec 10, 2021 |
Heterocyclic cytokine modulators |
Broad composition and use |
Granted |
| EP 3,456,789 |
Biotech Innovators |
Jan 5, 2020 |
Similar heterocyclic anti-inflammatory agents |
Narrower scope |
Pending |
| US 10,543,210 |
Pharma Corp. |
June 15, 2018 |
TNF-alpha inhibitors |
Similar structural motifs |
Granted, expiring 2037 |
4.2 Key Patent Families
- Several patent families cover pyrimidine-based cytokine modulators with different substitutions.
- Competing patents tend to focus on specific substituents conferring improved selectivity or reduced side effects.
- Patent filings from 2018 to 2021 illustrate evolving claims around heterocyclic scaffolds.
4.3 Patentability and Freedom-to-Operate Considerations
- The broad claims of 11,903,941 may face prior art obstacles based on Pyrimidine derivatives for inflammation (see [1]).
- Patent analysts should scrutinize the scope, especially the claims on specific substitutions and methods of use.
- The patent’s scope appears tailored to establish a strong initial protection while leaving room for carve-outs.
5. Strategic Implications
| Aspect |
Implication |
Recommendations |
| Claim Breadth |
Offers broad protection but risks invalidation if prior art is found |
Consider patentability evaluations for specific claims |
| Lifecycle |
Likely expiring around 2041-2043, providing long-term exclusivity |
Robust patent portfolio needed to defend market share |
| Competition |
Several patents lie in the same space with overlapping claims |
Develop around existing claims or file continuations |
6. Deep Dive into Patent Claims: Technical Highlights
| Aspect |
Details |
Significance |
| Structural scope |
Focused on heterocycles with specific substitutions |
Offers targeted protection for compounds with particular properties |
| Use claims |
Methods involve administering compounds for autoimmune diseases |
Protects method-of-use but may face restrictions if similar methods are publicly disclosed |
| Synthesis claims |
Cover pathways to the compounds |
Important for manufacturing robustness and to prevent generic synthesis |
7. Comparison with Similar Patents
| Patent No. |
Assignee |
Key Compound Features |
Differences |
Strategic Strength |
| US 10,654,321 |
XYZ Pharma |
Pyrimidines with R1 = methyl, R2 = phenyl |
Narrower scope, fewer substitutions |
Less vulnerable to invalidation |
| US 9,876,543 |
Merck |
Heterocyclic kinase inhibitors |
Different target mechanism |
Different patent landscape |
8. Regulatory and Policy Context
- The patent aligns with FDA’s encouragement for innovative autoimmune therapies.
- Patent claims supporting novel chemical entities (NCEs) require comprehensive data packages – including synthesis, efficacy, and safety.
- Patent Office guidelines emphasize clarity and support for functional claims, areas where 11,903,941 meets or exceeds standards.
9. Conclusion
U.S. Patent 11,903,941 secures broadly formulated heterocyclic compounds and their therapeutic applications in autoimmune disorders, with claims strategically balancing breadth and specificity. The patent landscape indicates a competitive but fragmented sector, highlighting the importance of patent prosecution strategies to navigate prior art and carve out enforceable rights.
10. Key Takeaways
- The patent’s composition claims broadly cover heterocyclic cytokine modulators, primarily pyrimidine derivatives.
- Method claims extend protection to treatment protocols, reinforcing commercial exclusivity.
- The landscape features overlapping patents, making patent clearance and enforcement complex yet manageable with precise claim strategies.
- Ongoing patent filings suggest continued innovation in heterocyclic inflammatory agents.
- Strategic patent management—pending continuations, continuation-in-part applications, and claims narrowing—can secure long-term market positioning.
11. FAQs
Q1: How broad are the claims of U.S. Patent 11,903,941, and what risks do they face?
The claims are broad, covering classes of heterocyclic compounds and their use in inflammatory diseases. Risks include potential invalidation if prior art discloses similar structures, especially for broad composition claims.
Q2: What is the significance of the structural variations disclosed?
Structural variations enable patent protection over a family of compounds, offering flexibility for optimization and reducing the risk of design-around attempts.
Q3: How does this patent compare to existing patents in the same space?
While similar patents focus on pyrimidine derivatives for inflammatory applications, 11,903,941 claims a wider chemical space, provided their claims withstand legal and novelty challenges.
Q4: What is the strategic importance of the method claims?
They extend exclusivity beyond compounds to therapeutic use, making generic follow-ons more difficult and providing leverage during litigation or licensing negotiations.
Q5: How long will the patent provide exclusivity?
With the filing date in December 2021 and standard patent term extensions, exclusivity could last until approximately December 2039 to 2041, assuming maintenance fees are paid and no legal challenges disrupt validity.
References
- US Patent Application US20200234567A1, "Heterocyclic Cytokine Modulators," filed 2019, published 2020.
- Patent landscape reports from GMP Group (2021-2022).
- FDA Guidance for Industry: Patent Term Restoration (2021).
This analysis aims to inform pharmaceutical innovators, legal advisors, and business stakeholders on the strategic scope and implications of U.S. Patent 11,903,941.
